Recently, there have been remarkable developments in the treatment of lysosomal storage disorders. This has been prompted in part by the involvement of pharmaceutical companies, who have given incentives through the implementation of orphan drug regulations that provide marketing exclusivity and other commercial benefits. As is true for more common chronic diseases (e.g. diabetes), these new therapies do not cure the patients; rather, they stabilize organ functions or just slow the progression of the disorder, particularly as most treatments started at a late stage of the disease. In addition, because of the broad clinical variability of these conditions, the benefit of a therapy cannot be predicted in an individual patient. This review summarizes the treatments that have already been approved for lysosomal storage disorders and those that have received an orphan drug status (Table I) .
SUPPORTIVE CARE
Since lysosomal storage disorders are multisystemic conditions, a multidisciplinary approach with a team of experienced specialists is mandatory for supportive care. In addition, to provide adequate care and to prevent complications (e.g. of the airways, and manifestations in the skeletal system and central nervous system [CNS] ), patients often need surgical procedures, and several medical devices such as orthoses, hearing aids, or special glasses. For most patients, physiotherapy is also necessary. Supportive care guidelines are available for several lysosomal storage disorders, including mucopolysaccharidoses (MPS) I and II, 1, 2 metachromatic leukodystrophy, 3 and Niemann-Pick disease type C (NPC). 4 
HAEMATOPOIETIC STEM CELL TRANSPLANTATION
Before the development of enzyme replacement therapies (ERTs; see below), haematopoietic stem cell transplantation (HSCT) was the only way of treating a lysosomal storage disorder. The rationale underlying HSCT is that donor cells can migrate into the recipient's organs and correct the metabolic defect by locally releasing the missing enzyme. For example, in the CNS, the microglia cells are partly replaced by donor cells and hence can deliver enzymes to the neurons. However, since this process is slow and incomplete, the success in treating severe neurological disease is limited. Despite this, for some lysosomal diseases, including the severe form of MPS I (Hurler disease), HSCT remains the first choice of treatment. Although very few controlled studies have used this approach, HSCT has been shown to increase life expectancy and improve clinical manifestation in children affected by Hurler disease when performed early in life. 5 In other MPS types, HSCT was not as successful as in Hurler disease, and ERTs or other therapeutic approaches have been developed or are likely to be in the future.
ENZYME REPLACEMENT THERAPY
The goal of ERT is to compensate metabolic defects in patients with lysosomal storage disease by weekly or fortnightly infusions of recombinant enzymes. Using a specific receptor, mostly the mannose-6-phosphate receptor, the intravenously applied enzymes can be taken up by cells and transported to the lysosomes where they perform their catalytic functions. The therapeutic enzymes may be produced from genetically modified cells from different organisms such as animals, humans, plants, or eggs. ERT has been shown to be effective in reducing storage material (e.g. reduction of glycosaminoglycans [GAGs] in MPS disorders, reduction of globotriaosylceramide in Fabry What this paper adds
• For a few lysosomal storage disorders, new therapies are available or under development.
• These therapies include enzyme replacement therapy, small molecules, and gene therapy.
• The new therapies cannot cure patients, but can stabilize organ function or slow progression.
disease), reducing organomegaly (liver, spleen, heart), and even in improving some organ function (e.g. heart function in Fabry disease or liver function in acid lipase deficiency).
There is great variability in clinical efficacy for several reasons: patients exhibit a broad variation in clinical manifestations, and severely affected patients with irreversible organ damage may not respond to ERT if it is initiated after damage has been established. In addition, the therapeutic effect may be hampered by the development of antibodies towards the recombinant enzyme (e.g. in patients with the severe infantile form of Pompe disease who have a high risk of immune response that leads to complete inefficacy of ERT). 6 Moreover, there is considerable difficulty targeting the recombinant enzymes to tissues that are not easily reached through the systemic circulation, including bone, cartilage, or brain.
To deliver recombinant enzyme to the brain, intrathecal infusion was performed in a phase 1/2 study in 12 patients with MPS IIIA (Sanfilippo disease A) who received recombinant human heparan-N-sulfatase through an intrathecal drug delivery device. 7 The procedure was well tolerated, and after 26 weeks of treatment a significant decline in GAG levels in the cerebrospinal fluid was observed; however, to fully assess this approach, further studies are necessary. In addition, enzymes have been modified to facilitate them to cross the blood-brain barrier. For example, the transport of a-iduronidase (IDUA), the enzyme deficient in MPS I, can be enhanced by fusion to a monoclonal antibody against the human insulin receptor, called HIRMAb. Based on animal studies that demonstrated proof of principle of this procedure, a phase 1/2 trial was performed in which patients affected by MPS I (Hurler syndrome) received the HIRMAb-IDUA fusion protein by intravenous infusion. After 13 weeks of treatment an improvement in neurological and cognitive functions was observed in some patients, and somatic effects were demonstrated by stabilization of urinary GAG levels and liver/spleen volume, and an improvement in shoulder motion. 8 These preliminary results provide the first indication of the clinical efficacy of a fusion enzyme for the CNS manifestation in patients with MPS I, but they must also be confirmed in other lysosomal storage disorders with brain involvement.
SUBSTRATE REDUCTION
Substrate reduction is a therapeutic approach that aims to slow the production of storage material instead of degrading it. For example, the imino sugar N-butyldeoxynojirimycin strongly inhibits ceramide glucosyltransferase, the enzyme that synthesizes glucosylceramide, the storage compound in Gaucher disease. 9 Miglustat (trade name Zavesca), a commercial formulation of this sugar, is approved for treating patients with Gaucher disease who have mild to moderate clinical manifestation and for whom ERT is not an option. Recently, the drug eliglustat (Cerdelga), a more specific ceramide glucosyltransferase inhibitor, has also gained marketing approval in the USA and Europe for treating Gaucher disease.
Another example is NPC, a neurovisceral disorder caused by mutations in either the NPC1 or the NPC2 gene. These genes encode proteins that are responsible for intracellular lipid trafficking, and a mutation in one of them leads to accumulation of cholesterol, sphingosine, sphingomyelin, and glycosphingolipids, particularly in the CNS. Since miglustat inhibits the synthesis of glycosphingolipids and is available in Europe, it has been repurposed for treating NPC. Analysis of data from an NPC registry revealed that miglustat can stabilize or even improve the disability status in most patients who received this treatment for 2 years or longer. 10 Genistein, a natural isoflavin that inhibits GAG synthesis, has also been used in some patients with MPS, although a placebo-controlled clinical trial in those with MPS III did not show any significant clinical benefit.
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Compared with ERT, substrate reduction therapy has some advantages: these molecules can be given orally, they do not generate immune reactions, and they have the potential to cross the blood-brain barrier. However, this therapeutic option is currently only available for two lysosomal storage disorders.
CHAPERONE THERAPY
All cells possess efficient mechanisms that control the exact folding of newly synthesized enzymes, and misfolded or mutant proteins are degraded by proteasomes. Specific molecules, termed 'chaperones' (e.g. Bip, heat shock protein, and calnexin), normally help proteins fold into their appropriate conformation. In the case of many lysosomal storage diseases, missense mutations result in the abnormal folding of lysosomal enzymes, preventing them from reaching the lysosome and fulfilling their function. In some cases, these mutant enzymes might regain at least partial catalytic activity if they can acquire their correct conformation. This is the basis of 'chaperone therapy' for lysosomal storage disorders.
As an example, the imino sugar migalastat (1-deoxygalactonojirimycin) is a competitive inhibitor of the enzyme a-galactosidase that is deficient in patients with Fabry disease. At sub-inhibitory concentrations, migalastat can act as a chemical chaperone leading to correct conformation of the mutant enzyme, thereby increasing its catalytic activity. After preclinical studies in animals and human cells demonstrated the safety and efficacy of migalastat, a clinical trial evaluated its effect on renal function in patients with Fabry disease who had been previously treated with ERT, as well as its effects on the heart, patient-reported outcomes, and safety. The results showed that migalastat was generally safe and well tolerated, and that it had clinical effects comparable to that of ERT. 12 Because of the results of this study, migalastat (trade name Galafold) has received marketing approval in Europe.
Chaperones may also be used in combination with ERT, as is the case with Pompe disease (a-glucosidase deficiency). In a clinical study, 25 patients with Pompe disease received duvoglustat HCl (AT2220, 1-deoxynojirimycin), an investigational pharmacological chaperone, given orally in escalating doses in addition to ERT with the recombinant enzyme alglucosidase alfa. By co-administration of alglucosidase alfa with duvoglustat, the a-glucosidase enzyme activity and protein in plasma increased about twofold compared with ERT alone. In general, duvoglustat was well tolerated, without drug-related adverse events. 13 Despite these successes, there are some clear disadvantages of chemical chaperones that limit their application in clinical practice, including the facts that they are mutation specific and that some of the mutations are unresponsive. Secondly, because chemical chaperones bind to the catalytic site of the enzymes, there may be a risk that at high concentrations they inhibit activity instead of enhancing it. Therefore, it is a great challenge to find the optimal dosage and administration regimen to maximize substrate turnover.
GENE THERAPY
Lysosomal storage disorders are excellent candidates for gene therapy since they are well-characterized single-gene disorders and the enzyme expression is generally not subject to complex regulation mechanisms. Furthermore, it has been shown that an enzyme activity of only 10% of the normal level is sufficient for clinical efficacy.
14 Gene therapy can be accomplished in two general ways, in vivo and ex vivo, which are both discussed below.
In vivo gene therapy
This approach has been successfully demonstrated in several animal model systems.
14 It involves the direct delivery of a gene into an organ such as the liver or lung so that the gene product (enzyme) will not only correct the local cells but will also be secreted at high levels and subsequently recaptured by other target cells via the mannose-6-phosphate receptor. Since the secreted enzyme cannot cross the blood-brain barrier, the benefits of this approach are generally limited to the peripheral organs, although recent studies have also shown effective gene delivery and expression after direct injection into the CNS.
For example, experiments in animals have demonstrated that gene therapy using an adeno-associated virus vector, directly injected into the brain, is efficient and safe. Based on these preclinical studies, a phase I/II clinical trial was initiated in patients affected by MPS type IIIA (Sanfilippo disease type A), a lysosomal storage disorder that is caused by the deficiency of the enzyme heparan-N-sulfamidase. In this study, four children aged between 2 years 8 months and 6 years received intracerebral injections of an adenoassociated virus vector carrying the complementary DNA encoding sulfamidase and the gene for the sulfatase-modifying factor SUMF1. 15 The therapeutic vector was administered to the brain by stereotaxic surgery through 12 needles. Immunosuppressive treatment was given 2 weeks before the procedure, which was generally well tolerated. One month before and 1 year after surgery, magnetic resonance imaging evaluated brain size and neuropsychological tests were performed. In two patients, brain atrophy seemed to be stable, but tended to increase in the other two individuals. In three patients, moderate improvements in behaviour, attention, and sleep were suggested by neuropsychological evaluations.
Intracerebral injections of adeno-associated viruses carrying a therapeutic gene have also been performed or are under evaluation in other lysosomal storage disorders and neurodegenerative diseases (e.g. MPS type IIIB [Sanfilippo disease type B], metachromatic leukodstrophy, and Parkinson disease). 16 
Ex vivo therapy
The blood-brain barrier prevents circulating enzymes from entering the CNS. Haematopoietic cells can cross this barrier, where they subsequently differentiate into microglia. This forms the basis of HSCT in patients with neurological lysosomal storage disorders, a procedure that may be beneficial but is associated with significant risks of graft failure or graft versus host disease and can lead to death. These complications may be circumvented by transplantation of autologous haematopoietic stem cells that have been genetically modified to express the missing protein.
For example, a lentiviral vector was used in a clinical trial performed by Biffi et al. 17 on three children affected by metachromatic leukodystrophy (arylsulfatase A deficiency) who did not yet show any symptoms. In this study, the arylsulfatase A gene was transferred ex vivo into haematopoietic stem cells of the patients. After reinfusion of the genetically modified cells, high enzyme activity was found throughout haematopoietic lineages and in the cerebrospinal fluid. The disease did not manifest or progress in any of the treated children, even after the time at onset predicted from sibling cases. 17 Several other lysosomal storage diseases are also being evaluated using a similar ex vivo approach.
Despite these promising results there are still several issues and questions about the long-term safety and efficacy of gene therapy before it becomes a realistic option for patients affected by lysosomal storage disorders.
CRISPR/Cas9 technique
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/caspase 9) is a relatively new technique that has the potential to correct specific genetic defects without long-term deleterious side effects. 18 A schematic depiction of this technique, which is based on the use of a guide ribonucleic acid to direct a 'molecular scissor' to a specific site in the genome and cut double-stranded DNA by the endonuclease caspase 9, is shown in Figure 1 . Thereafter, the double-stranded DNA breaks are repaired by adding donor DNA, finally leading to a controlled gene modification. Although this new technique raises the potential for specific correction of genetic defects, some concerns remain about the specificity of the method and its longterm safety. For example, the use of this technique in a mouse resulted -in addition to the repair of the targeted gene -in secondary mutations in regions of the genome that were not targeted by the single guide ribonucleic acid. 19 Therefore, more animal and in vitro studies are needed to validate the reliability of the CRISPR/Cas9 technique before it can be used widely in humans.
STOP-CODON READ-THROUGH
In many lysosomal storage disorders, premature stopcodon mutations (also referred to as 'nonsense mutations') have been identified as leading to premature translation termination and formation of truncated, non-functional enzymes. 20 For many years it has been known that certain low-molecular-mass drugs (e.g. gentamicin) are able to induce the read-through of premature stop-codons and to restore production of full-length proteins with subnormal or even normal enzymatic activities. Experimental studies have further shown that enhanced stop-codon readthrough could be used as a therapeutic approach for different genetic diseases, including Duchenne muscular dystrophy and cystic fibrosis. 20 The use of gentamycin for chronic, long-term nonsense suppression is limited because of its toxic side effects such as hearing loss and kidney damage, leading to a search to find new drugs with similar read-through properties.
In the severe form of MPS I, Hurler syndrome (IDUA deficiency), the two most common mutations of the IDUA gene encoding iduronidase are the premature stop-codons Q70X and W402X, which are responsible for approximately 70% of disease alleles in patients with this disorder. In cell culture experiments, Keeling et al. demonstrated that by the addition of gentamicin to Hurler syndrome fibroblast cell lines heterozygous for the IDUA stop mutations Q70X and W402X, the IDUA activity could be increased to 2.8% of the normal level. 21 The positive effect of nonsense suppression therapy on organ manifestations could be further demonstrated in an animal model: Idua tm1Kmke mice carrying a mutation homologous to the human IDUA-W402X nonsense mutation were treated with the designer aminoglycoside NB84. After 28 weeks of treatment, a significant increase in iduronidase activity in several organs, a reduction in GAG accumulation, and an improvement in heart function and general activity of the animals were observed. 22 In many other cell culture and animal studies of lysosomal storage disorders, it has been demonstrated that several aminoglycoside derivatives are capable of increasing enzyme levels and even improving organ manifestations. 23 A first clinical trial of nonsense suppression therapy in patients with Hurler disease will be initiated soon.
OTHER NOVEL THERAPIES
Many other compounds (e.g. the antiinflammatory drug pentosan polysulfate for treating mucopolysaccharidoses, 24 or arimoclomol, a small-molecule inducer of the heat shock protein for NPC 25 ) have been developed and will be or are already applied in clinical trials. Based on positive effects in animal models, cyclodextrin, a cyclic oligosaccharide, was used as an experimental drug in patients with NPC, although its mechanism of action is not yet fully understood. The few published cases of patients who received this drug intrathecally suggest some improvements in neurological function and stabilization in the progression of the disease. 26 Clinical trials are being performed to evaluate the safety and efficacy of this approach in a controlled setting.
CONCLUSION
As ERT and HSCT only have a very limited effect on brain, bone, and cardiac and connective tissue, there is still an unmet clinical need for new drugs that can access these organs. In the future, it can be expected that more effective therapies (e.g. modified enzymes or gene therapy, personalized medicine such as read-through drugs, and early initiation of treatment) may completely change the prospect for patients affected by lysosomal storage disorders. To facilitate a timely start to therapeutic intervention before any clinical manifestation occurs, newborn screening programmes for lysosomal storage disorders have also been developed in several countries, 27 and pilot studies have demonstrated that screening is likely to identify many more patients than previously expected from population studies. However, this means that many individuals with a positive screening result will develop symptoms only in late adulthood or perhaps never in their lives, raising the question about the value of their therapy. As it is not possible to give a clear answer to this question -namely which individuals found by screening of newborn infants should be treated early or later, or even never, in their life -this diagnostic approach cannot generally be recommended. 28 
